Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H32N6O12 |
Molecular Weight | 812.7365 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OC[C@@H](OC(=O)C1=CN=CC=C1)[C@@H](OC(=O)C2=CN=CC=C2)[C@H](OC(=O)C3=CN=CC=C3)[C@H](COC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5)C6=CN=CC=C6
InChI
InChIKey=IMRLNFKFNFLWQF-IYKITFJXSA-N
InChI=1S/C42H32N6O12/c49-37(27-7-1-13-43-19-27)55-25-33(57-39(51)29-9-3-15-45-21-29)35(59-41(53)31-11-5-17-47-23-31)36(60-42(54)32-12-6-18-48-24-32)34(58-40(52)30-10-4-16-46-22-30)26-56-38(50)28-8-2-14-44-20-28/h1-24,33-36H,25-26H2/t33-,34+,35-,36-/m1/s1
D-glucitol hexanicotinate (sorbinicate, SN) is a derivative of nicotinic acid. In rabbits kept on a diet containing 1 g/day cholesterol for 12 weeks, sorbinicate displayed greater hypolipemic and antiatherogenic activity than an equidose of plain nicotinic acid at much lower and more constant plasma nicotinic acid levels. By modulating the bioavailability of nicotinic acid, sorbinicate maintains and in some cases enhances the pharmacological activity of the acid, avoiding at least some of its major side effects. Sorbinicate has effective lipid-lowering activity; the combination of hypolipidemic and anti-aggregating properties may prove important in primary and secondary prevention of atherosclerotic disease. It is suggested that the antilipolytic activity of sorbinicate is at least partly mediated by an inhibition of glucagon secretion (and/or synthesis).
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Comparative evaluation of some pharmacological properties and side effects of D-glucitol hexanicotinate (sorbinicate) and nicotinic acid correlated with the plasma concentration of nicotinic acid. | 1980 May |
|
Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate). | 1983 |
|
Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease. | 1984 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6746150
D-glucitol-hexanicotinate (sorbinicate) was administered at a daily dose of 1.6 mg to 16 male patients who had survived myocardial infarction.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3807
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
38Y76163XT
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
C152406
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103972
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
3058386
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
100000083771
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
SUB10595MIG
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
C015238
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
6184-06-1
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY | |||
|
2460
Created by
admin on Sat Dec 16 17:55:09 GMT 2023 , Edited by admin on Sat Dec 16 17:55:09 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD